Company Encyclopedia
View More
name
GDK Biotech
688670.SH
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia. The company was founded in 2008 and is based in Taizhou, China.
1.558 T
688670.SHMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking58/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-10.09%D
    • Profit Margin-108.54%E
    • Gross Margin64.28%A
  • Growth ScoreB
    • Revenue YoY121.40%A
    • Net Profit YoY-11.59%D
    • Total Assets YoY-7.06%D
    • Net Assets YoY-9.60%D
  • Cash ScoreB
    • Cash Flow Margin-92.13%D
    • OCF YoY121.40%A
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreA
    • Gearing Ratio17.75%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GDK Biotech released its performance for the first three quarters, with a net loss attributable to the parent company of 86.47 million yuan

    According to the Zhitong Finance APP, GDK Biotech disclosed its third-quarter report for 2025. The company achieved revenue of 74.66 million yuan in the first three quarters, a year-on-year increase of 91.93%; the net profit attributable to shareholders was a loss of 86.47 million yuan; the net profit excluding non-recurring gains and losses was a loss of 91.11 million yuan; basic earnings per share were -0.70 yuan

    Zhitong·
    SH
    688670
    -1.13%
    Zhitong·
    SH
    688670
    -1.13%

    GDK Biotech: Vice President Song Bin resigns for personal reasons

    Recently, the board of directors of Jiangsu GDK Biotech Co., Ltd. received a resignation letter from Vice President Song Bin. Song Bin applied to resign from the position of Vice President for personal reasons and will no longer hold any position in the company after his resignation. His original term was set to end on May 10, 2026, but his actual departure date is September 30, 2025. Song Bin has completed the handover of his work, and his resignation will not adversely affect the company's production and operations. As of the announcement disclosure date, he did not hold any company stock and had no unfulfilled commitments

    Zhitong·
    SH
    688670
    -1.13%
    Zhitong·
    SH
    688670
    -1.13%

    GDK Biotech General Manager Zhang Jianhui passed away due to illness

    According to the Zhitong Finance APP, GDK Biotech announced that the company received a notification from the family of General Manager Mr. Zhang Jianhui that Mr. Zhang Jianhui unfortunately passed away due to illness recently, at the age of 67

    Zhitong·
    SH
    688670
    -1.13%
    Zhitong·
    SH
    688670
    -1.13%

    GDK Biotech issued the first batch of flu vaccine approvals in 2025

    On September 1st, the China Food and Drug Administration Research Institute announced that GDK Biotech's first batch of influenza vaccines for 2025 has been issued

    Zhitong·
    SH
    688670
    -1.13%
    Zhitong·
    SH
    688670
    -1.13%

    GDK Biotech released its performance for the first half of the year, with a net loss attributable to the parent company of 39.6531 million yuan

    According to the Zhitong Finance APP, GDK Biotech released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 3.5242 million yuan, a year-on-year increase of 7.18%. The net loss attributable to shareholders of the listed company was 39.6531 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.9408 million yuan, with a basic loss per share of 0.32 yuan

    Zhitong·
    SH
    688670
    -1.13%
    Zhitong·
    SH
    688670
    -1.13%
    © 2025 Longbridge｜Disclaimer